Alpha Cognition Begins Patient Enrollment in ZUNVEYL RESOLVE Study
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 4 days ago
0mins
Alpha Cognition announced the enrollment of the first patient in RESOLVE, a Phase 4 post-marketing clinical study designed to further evaluate the tolerability profile and treatment experience associated with ZUNVEYL in routine clinical practice. The RESOLVE study is expected to enroll approximately 150 patients across multiple clinical sites and will monitor adverse events, treatment persistence, and discontinuation rates throughout the study. Data generated from RESOLVE is expected to complement findings from previous clinical studies and contribute to the growing body of evidence supporting the use of ZUNVEYL in clinical practice.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy ACOG?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on ACOG
Wall Street analysts forecast ACOG stock price to rise
1 Analyst Rating
1 Buy
0 Hold
0 Sell
Moderate Buy
Current: 6.680
Low
18.00
Averages
18.00
High
18.00
Current: 6.680
Low
18.00
Averages
18.00
High
18.00
About ACOG
Alpha Cognition Inc. is a commercial stage, biopharmaceutical company dedicated to developing treatments for patients suffering from neurodegenerative diseases, such as Alzheimer’s disease and Cognitive Impairment with mild Traumatic Brain Injury (mTBI). The Company's ZUNVEYL (benzgalantamine) product is a delayed release oral tablet formulation indicated for the treatment of mild to moderate dementia of the Alzheimer’s type in adults. Its pre-clinical development programs include ZUNVEYL in combination with memantine for the treatment of moderate-to-severe Alzheimer’s disease; ALPHA-1062 sublingual formulation; ALPHA-1062 intranasal formulation for the treatment of cognitive impairment with mTBI; ALPHA-0602; ALPHA-0702 & ALPHA-0802 (Progranulin and Progranulin GEM’s) for the treatment of neurodegenerative diseases including amyotrophic lateral sclerosis or Lou Gehrig’s disease and spinal muscular atrophy, and ALPHA-1062 for the treatment of acute pancreatitis.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Alpha Cognition Launches RESOLVE Study for ZUNVEYL
- Study Launch: Alpha Cognition announced the enrollment of the first patient in the RESOLVE study, which aims to evaluate the tolerability of ZUNVEYL in Alzheimer's patients, with approximately 150 patients expected to be enrolled, demonstrating the company's commitment to long-term drug efficacy.
- Clear Research Objectives: The RESOLVE study will collect safety and tolerability data while exploring changes in neuropsychiatric symptoms related to Alzheimer's disease, which not only aids physicians in making informed treatment decisions but also enhances patient treatment experiences.
- Data Complementation: Data generated from this study will complement previous clinical findings, further supporting the use of ZUNVEYL in clinical practice, reflecting the company's ongoing commitment to drug development.
- Long-Term Outlook: Alpha Cognition expects patient enrollment to continue through the second quarter of 2027, with study results providing crucial evidence for the market promotion of ZUNVEYL, aiding the company's strategic positioning in the neurodegenerative disease treatment sector.
See More
Alpha Cognition Q1 Earnings Beat Expectations
- Earnings Beat Expectations: Alpha Cognition reported a Q1 GAAP EPS of -$0.32, exceeding market expectations by $0.08, indicating improvements in cost management despite still being in a loss position.
- Revenue Misses Slightly: The reported revenue of $3.54M fell short of the anticipated $3.63M, reflecting challenges in sales growth that could impact investor confidence moving forward.
- Market Reaction Analysis: While the earnings beat may provide some positive sentiment, the revenue miss could lead to short-term stock price volatility, prompting investors to closely monitor the company's strategic adjustments and market performance.
- Future Outlook: The company needs to enhance its sales strategies to boost revenue and ensure sustained growth in a competitive market, particularly focusing on new product launches and market expansion.
See More
Alpha Cognition to Host Q1 2026 Earnings Call on May 14
- Earnings Release Schedule: Alpha Cognition Inc. will report its Q1 2026 financial results and provide a business update on May 14, 2026, at 4:30 PM ET, which is expected to significantly impact investor sentiment.
- Conference Call Details: Following the earnings release, the company will host a conference call for detailed discussions on financial and operational results, with participants able to join via 1-877-407-9039 or 1-201-689-8470, enhancing transparency and investor engagement.
- New Drug Development Progress: Alpha Cognition is developing ZUNVEYL®, a next-generation treatment for Alzheimer's disease, which is anticipated to fill a market gap with minimal gastrointestinal side effects and a unique mechanism of action, presenting substantial commercial potential.
- Forward-Looking Statements: The news release includes forward-looking statements that highlight potential market risks and uncertainties, urging investors to consider various factors that may affect the company's future performance.
See More
Alpha Cognition Appoints New Board Member
- New Board Appointment: Alpha Cognition has appointed Bethany Sensenig to its Board of Directors, effective April 15, 2026, bringing decades of leadership experience in the pharmaceutical and biotechnology sectors, which is expected to significantly aid the company's commercial launch of ZUNVEYL and the development of its sublingual program.
- Financial and Strategic Expertise: Sensenig previously served as CFO at Radius Health, where she played a crucial role in driving growth and financial performance, and her extensive experience is anticipated to enhance Alpha Cognition's operational efficiency and financial health in the competitive biopharmaceutical market.
- Board Transition: Len Mertz has informed the company that he will not seek re-election to the Board, and as a founding member, he provided valuable leadership in advancing the company to public markets and progressing its pipeline, with management expressing gratitude for his contributions.
- Future Outlook: Alpha Cognition is dedicated to developing treatments for neurodegenerative diseases, with ZUNVEYL being a novel drug for Alzheimer's disease, expected to carve out a niche in the market due to its unique mechanism of action and minimal side effects.
See More
Alpha Cognition Grants Stock Options to New Employee
- Stock Option Grant: On April 14, 2026, Alpha Cognition granted 20,000 nonstatutory stock options to a new non-executive employee, aimed at attracting talent in accordance with Nasdaq Listing Rule 5635(c)(4).
- Exercise Price Setting: Each stock option has an exercise price of $6.49 per share, based on the closing price on April 14, 2025, which helps incentivize employees to grow alongside the company.
- Vesting Arrangement: The stock options will vest over three years, with 25% vesting after one year and the remainder vesting monthly, ensuring long-term employee commitment and contribution.
- Company Background: Alpha Cognition focuses on developing treatments for Alzheimer's disease and mild traumatic brain injury, with ZUNVEYL as a new generation drug expected to have minimal gastrointestinal side effects, showcasing the company's innovative potential in neurodegenerative diseases.
See More
Alpha Cognition Secures New Patent for TBI Treatment
- Patent Issuance: The U.S. Patent and Trademark Office granted Alpha Cognition U.S. Patent No. 12,589,099 on March 31, 2026, covering methods for treating traumatic brain injury (TBI) with ALPHA-1062, which strengthens the company's intellectual property portfolio and is expected to enhance its market competitiveness.
- Significant Market Potential: The total addressable market for traumatic brain injury is estimated at $14 billion, with no approved therapies currently available, providing Alpha Cognition with a compelling first-mover advantage to address this significant unmet medical need.
- Strategic Expansion: CEO Michael McFadden noted that this patent marks an important milestone in expanding the company's platform beyond Alzheimer's disease, underscoring the innovation behind ALPHA-1062 while reinforcing the long-term value of ZUNVEYL.
- Investor Confidence: By advancing ALPHA-1062 into the TBI space, Alpha Cognition aims to address a large underserved patient population while enhancing the commercial potential of its pipeline, reflecting the company's commitment to delivering sustained shareholder value.
See More
Alpha Cognition Launches RESOLVE Study for ZUNVEYL
- Study Launch: Alpha Cognition announced the enrollment of the first patient in the RESOLVE study, which aims to evaluate the tolerability of ZUNVEYL in Alzheimer's patients, with approximately 150 patients expected to be enrolled, demonstrating the company's commitment to long-term drug efficacy.
- Clear Research Objectives: The RESOLVE study will collect safety and tolerability data while exploring changes in neuropsychiatric symptoms related to Alzheimer's disease, which not only aids physicians in making informed treatment decisions but also enhances patient treatment experiences.
- Data Complementation: Data generated from this study will complement previous clinical findings, further supporting the use of ZUNVEYL in clinical practice, reflecting the company's ongoing commitment to drug development.
- Long-Term Outlook: Alpha Cognition expects patient enrollment to continue through the second quarter of 2027, with study results providing crucial evidence for the market promotion of ZUNVEYL, aiding the company's strategic positioning in the neurodegenerative disease treatment sector.
See More
Alpha Cognition Q1 Earnings Beat Expectations
- Earnings Beat Expectations: Alpha Cognition reported a Q1 GAAP EPS of -$0.32, exceeding market expectations by $0.08, indicating improvements in cost management despite still being in a loss position.
- Revenue Misses Slightly: The reported revenue of $3.54M fell short of the anticipated $3.63M, reflecting challenges in sales growth that could impact investor confidence moving forward.
- Market Reaction Analysis: While the earnings beat may provide some positive sentiment, the revenue miss could lead to short-term stock price volatility, prompting investors to closely monitor the company's strategic adjustments and market performance.
- Future Outlook: The company needs to enhance its sales strategies to boost revenue and ensure sustained growth in a competitive market, particularly focusing on new product launches and market expansion.
See More
Alpha Cognition to Host Q1 2026 Earnings Call on May 14
- Earnings Release Schedule: Alpha Cognition Inc. will report its Q1 2026 financial results and provide a business update on May 14, 2026, at 4:30 PM ET, which is expected to significantly impact investor sentiment.
- Conference Call Details: Following the earnings release, the company will host a conference call for detailed discussions on financial and operational results, with participants able to join via 1-877-407-9039 or 1-201-689-8470, enhancing transparency and investor engagement.
- New Drug Development Progress: Alpha Cognition is developing ZUNVEYL®, a next-generation treatment for Alzheimer's disease, which is anticipated to fill a market gap with minimal gastrointestinal side effects and a unique mechanism of action, presenting substantial commercial potential.
- Forward-Looking Statements: The news release includes forward-looking statements that highlight potential market risks and uncertainties, urging investors to consider various factors that may affect the company's future performance.
See More
Alpha Cognition Appoints New Board Member
- New Board Appointment: Alpha Cognition has appointed Bethany Sensenig to its Board of Directors, effective April 15, 2026, bringing decades of leadership experience in the pharmaceutical and biotechnology sectors, which is expected to significantly aid the company's commercial launch of ZUNVEYL and the development of its sublingual program.
- Financial and Strategic Expertise: Sensenig previously served as CFO at Radius Health, where she played a crucial role in driving growth and financial performance, and her extensive experience is anticipated to enhance Alpha Cognition's operational efficiency and financial health in the competitive biopharmaceutical market.
- Board Transition: Len Mertz has informed the company that he will not seek re-election to the Board, and as a founding member, he provided valuable leadership in advancing the company to public markets and progressing its pipeline, with management expressing gratitude for his contributions.
- Future Outlook: Alpha Cognition is dedicated to developing treatments for neurodegenerative diseases, with ZUNVEYL being a novel drug for Alzheimer's disease, expected to carve out a niche in the market due to its unique mechanism of action and minimal side effects.
See More
Alpha Cognition Grants Stock Options to New Employee
- Stock Option Grant: On April 14, 2026, Alpha Cognition granted 20,000 nonstatutory stock options to a new non-executive employee, aimed at attracting talent in accordance with Nasdaq Listing Rule 5635(c)(4).
- Exercise Price Setting: Each stock option has an exercise price of $6.49 per share, based on the closing price on April 14, 2025, which helps incentivize employees to grow alongside the company.
- Vesting Arrangement: The stock options will vest over three years, with 25% vesting after one year and the remainder vesting monthly, ensuring long-term employee commitment and contribution.
- Company Background: Alpha Cognition focuses on developing treatments for Alzheimer's disease and mild traumatic brain injury, with ZUNVEYL as a new generation drug expected to have minimal gastrointestinal side effects, showcasing the company's innovative potential in neurodegenerative diseases.
See More
Alpha Cognition Secures New Patent for TBI Treatment
- Patent Issuance: The U.S. Patent and Trademark Office granted Alpha Cognition U.S. Patent No. 12,589,099 on March 31, 2026, covering methods for treating traumatic brain injury (TBI) with ALPHA-1062, which strengthens the company's intellectual property portfolio and is expected to enhance its market competitiveness.
- Significant Market Potential: The total addressable market for traumatic brain injury is estimated at $14 billion, with no approved therapies currently available, providing Alpha Cognition with a compelling first-mover advantage to address this significant unmet medical need.
- Strategic Expansion: CEO Michael McFadden noted that this patent marks an important milestone in expanding the company's platform beyond Alzheimer's disease, underscoring the innovation behind ALPHA-1062 while reinforcing the long-term value of ZUNVEYL.
- Investor Confidence: By advancing ALPHA-1062 into the TBI space, Alpha Cognition aims to address a large underserved patient population while enhancing the commercial potential of its pipeline, reflecting the company's commitment to delivering sustained shareholder value.
See More
